RankAlpha logo
Back to Rankings

NVO

Novo Nordisk A/SB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The bull case is that Q1 confirmed Wegovy remains the growth engine: obesity care sales rose 22% at CER, the pill crossed 1 million users and 2 million cumulative prescriptions, and the May CHMP opinions create two additional EU launch paths. If access stays broad and pricing stabilizes, Novo can keep monetizing category leadership.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.2.
What can break
EU rollout still depends on final approvals, reimbursement, and market-by-market commercialization.
Momentum
23
Value
66
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $51.00 · Bull $58.00 · Bear $36.00Analysis 2026-06-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-10

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $44.50
Why
Momentum23 · Δ7d -17.3
Value66 · Δ7d -0.0
Sentiment76 · Δ7d +9.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +9.2.

Contradictions & invalidation

  • • EU rollout still depends on final approvals, reimbursement, and market-by-market commercialization.
  • • Lilly remains the clearest direct competitive threat in obesity and diabetes.
  • • The bear case is that pricing pressure is already visible: adjusted sales excluding the 340B reversal fell 4% at CER and U.S.

Catalyst clock

2026-05-06

Q1 2026 print confirmed Wegovy adoption, but pricing pressure remained

Lead driver: Sentiment · See AI snapshot
Momentum
23
9% active weight
Current posture
7d trendSoftening
Δ7d
-17.3
Δ21d
-3.8
Value
66
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+8.6
Sentiment
76
62% active weight
Current posture
7d trendImproving
Δ7d
+9.2
Δ21d
+4.3
Why this grade

Composite grade B. Momentum 23.2 / Value 65.8 / Sentiment 75.9

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-06. Scenario method

B+
Bull case
25%
Probability
Target price
$58.00
Analysis reference price unavailable
Analysis 2026-06-06 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$51.00
Analysis reference price unavailable
Analysis 2026-06-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$36.00
Analysis reference price unavailable
Analysis 2026-06-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$200.78B
Beta
1.44
Shares Out
3.35B
P/E (TTM)
14.9
P/S (TTM)
3.72
P/FCF (TTM)
127.96
Rev YoY
+4.6%
EPS YoY
-18.6%
Gross Margin
+80.7%
Op Margin
+45.4%
Net Debt
$16.35B
Current Ratio
0.87
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data